Choose TECVAYLI® (teclistamab-cqyv)

Power within reach for the 61.8% of patients who achieved ORR in MajesTEC-1¹

61.8%ORR^* (n=68/110 [95% CI, 52.1%-70.9%])

28.2^% ≥CR^†(n=31/110)29.1^% VGPR(n=32/110)4.5^% PR(n=5/110)

Includes 30-month follow-up data from
the MajesTEC-1 final analysis^2‡§

The first bispecific BCMA × CD3 T-cell engager given as an off-the-shelf subcutaneous injection for adult patients with RRMM who have received at least 4 prior lines of therapy, including a PI, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.^1,3

This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).¹

*ORR: sCR+CR+VGPR+PR.¹
^†≥CR: sCR+CR.¹
^‡Response data based on a median duration of follow-up of 29.9 months.⁴
^§Safety analysis based on a median follow-up of 30.4 months.^2,4

MajesTEC-1 study design: The efficacy of TECVAYLI^® was evaluated in patients with RRMM in a single-arm, open-label, multi-center, phase 1/2 study. The study included patients who had previously received at least 3 prior therapies, including a PI, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.¹

BCMA, B-cell maturation antigen; CD3, cluster of differentiation 3; CD38, cluster of differentiation 38; CI, confidence interval; CR, complete response; ORR, overall response rate; PI, proteasome inhibitor; PR, partial response; RRMM, relapsed or refractory multiple myeloma; sCR, stringent complete response; VGPR, very good partial response.

References:

TECVAYLI^® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
Garfall AL, Nooka AK, van de Donk NWCJ, et al. Long-term follow-up from the phase 1/2 MajesTEC-1 trial of teclistamab in patients with relapsed/refractory multiple myeloma. Poster. Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting; May 31-June 4, 2024; Chicago, IL.
U.S. Food and Drug Administration. FDA approves teclistamab-cqyv for relapsed or refractory multiple myeloma. Accessed June 24, 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-teclistamab-cqyv-relapsed-or-refractory-multiple-myeloma
Data on file. Janssen Biotech, Inc.

Choose TECVAYLI® (teclistamab-cqyv)

Need help?